Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer

Share this content:
One (4.2%) patient achieved complete response, and 7 patients (29.2%) achieved durable partial responses. The overall response rate (ORR) was 33.3% (95% CI, 15.6%-55.3%).
One (4.2%) patient achieved complete response, and 7 patients (29.2%) achieved durable partial responses. The overall response rate (ORR) was 33.3% (95% CI, 15.6%-55.3%).

Pembrolizumab demonstrated safety and promising efficacy in pre-treated patients with advanced, PD-L1-positive small-cell lung cancer (SCLC), according to a study published in the Journal of Clinical Oncology.1

For this phase Ib KEYNOTE-028 trial (ClinicalTrials.gov Identifier: NCT02054806), researchers enrolled 24 patients with PD-L1-expressing SCLC and administered at least 1 dose of pembrolizumab 10 mg/kg every 2 weeks.

One (4.2%) patient achieved complete response, and 7 patients (29.2%) achieved durable partial responses. The overall response rate (ORR) was 33.3% (95% CI, 15.6%-55.3%).

Safety was consistent with known safety profiles from previous studies. All patients experienced adverse effects (AE). Treatment-related toxicity was observed in 66.7% of patients, and the most frequently reported AEs were arthralgia, asthenia, rash, diarrhea, and cough.

RELATED: Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

Grade 3 to 5 AEs occurred in 8 patients. Two patients required interventions for AEs related to treatment, leading to discontinuation in 1 patient and death in the other.

Reference

  1. Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol. 2017 Aug 16. doi: 10.1200/JCO.2017.72.5069 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters